|
1
|
Cao L, Wan Q, Li F and Tang CE: miR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 51:456–461. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
GBD 2015 LRI Collaborators;. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Swartz S, Fullman N, Mosser J, Thompson RL, et al: Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 17:1133–1161. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Liu R, Guo H and Lu S: miR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med. 7:4598–4609. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Feng X, Liu N, Deng S, Zhang D, Wang K and Lu M: miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1alpha. Onco Targets Ther. 10:5899–5906. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Liu Y, Han S, Li Y, Liu Y, Zhang D, Li Y and Zhang J: MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line. Oncol Lett. 14:1780–1786. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Teng Y, Zuo X, Hou M, Zhang Y, Li C, Luo W and Li X: A double-negative feedback interaction between microRNA-29b and DNMT3A/3B contributes to ovarian cancer progression. Cell Physiol Biochem. 39:2341–2352. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zou J, Yin F, Wang Q, Zhang W and Li L: Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol. 8:6847–6858. 2015.PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, et al: Bone protection by inhibition of microRNA-182. Nat Commun. 9(4108)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Olive V, Minella AC and He L: Outside the coding genome, mammalian microRNAs confer structural and functional complexity. Sci Signal. 8(re2)2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ju J: Implications of miRNAs in colorectal cancer chemoresistance. Int Drug Discov. 2011(pii: 2063)2011.PubMed/NCBI
|
|
13
|
Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics. 2:171–185. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Siddik ZH: Cisplatin Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Deng H, Qianqian G, Ting J and Aimin Y: miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother. 106:1072–1081. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 53:644–658. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, Peng C and Xu Z: miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells. Front Genet. 9(555)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Deb B, Uddin A and Chakraborty S: miRNAs and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tan YY, Xu XY, Wang JF, Zhang CW and Zhang SC: miR-654-5p attenuates breast cancer progression by targeting EPSTI1. Am J Cancer Res. 6:522–532. 2016.PubMed/NCBI
|
|
20
|
Geraldo MV, Nakaya HI and Kimura ET: Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Oncotarget. 8:9597–9607. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xu C, Zheng Y, Lian D, Ye S, Yang J and Zeng Z: Analysis of microRNA expression profile identifies novel biomarkers for non-small cell lung cancer. Tumori. 101:104–110. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lu M, Wang C, Chen W, Mao C and Wang J: miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling. DNA Cell Biol. 37:381–388. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang S, Zhang X, Fu X, Li W, Xing S and Yang Y: Identification of common differentially-expressed miRNAs in ovarian cancer cells and their exosomes compared with normal ovarian surface epithelial cell cells. Oncol Lett. 16:2391–2401. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P and Gatti L: PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol. 310:9–19. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3(Article3)2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou H, Gao S and Zhang L: Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3. Cancer Cell Int. 18(208)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Vert JP, Foveau N, Lajaunie C and Vandenbrouck Y: An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics. 7(520)2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang Z and Zhu F: MicroRNA-100 is involved in shrimp immune response to white spot syndrome virus (WSSV) and Vibrio alginolyticus infection. Sci Rep. 7(42334)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Amini-Farsani Z, Sangtarash MH, Shamsara M and Teimori H: miR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway. Cytotechnology. 70:203–213. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK and Manavathi B: HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cell Oncol (Dordr). 40:133–144. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ullmark T, Montano G, Jarvstrat L, Jernmark Nilsson H, Håkansson E, Drott K, Nilsson B, Vidovic K and Gullberg U: Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells. Biochem Biophys Res Commun. 482:802–807. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yu X, Zheng H, Chan MT and Wu WK: Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am J Cancer Res. 7:1769–1778. 2017.PubMed/NCBI
|
|
34
|
Samuel P, Pink RC, Brooks SA and Carter DR: miRNAs and ovarian cancer: A miRiad of mechanisms to induce cisplatin drug resistance. Expert Rev Anticancer Ther. 16:57–70. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J and Wang Z: Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2(e75)2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang Y, Huang S, Guo Y and Li L: miR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother. 106:1357–1363. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, et al: DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics. 7:4118–4134. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li X, Jin Y, Mu Z, Chen W and Jiang S: MicroRNA-146a-5p enhances cisplatininduced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Int J Oncol. 51:327–335. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jiang Y, Jiang J, Jia H, Qiao Z and Zhang J: Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun. Cell Physiol Biochem. 51:129–141. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, Kim SH, Khoury CC, et al: De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat Med. 24:1351–1359. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, Ahrendt T, Adams S, Bode HB, Guillemin GJ, Wick W and Platten M: The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res. 73:3225–3234. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ishidoh K, Kamemura N, Imagawa T, Oda M, Sakurai J and Katunuma N: Quinolinate phosphoribosyl transferase, a key enzyme in de novo NAD(+) synthesis, suppresses spontaneous cell death by inhibiting overproduction of active-caspase-3. Biochim Biophys Acta. 1803:527–533. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, et al: 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Toxicol Appl Pharmacol. 325:48–60. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Teng P, Jiao Y, Hao M and Tang X: microRNA-383 suppresses the P13K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via downregulating PARP2. J Cell Biochem. 117:5243–5252. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang H, Gong J, Zhang H and Kong D: Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2. Int J Clin Exp Pathol. 8:4444–4456. 2015.PubMed/NCBI
|
